Search results
FOR OUR PATIENTS. Our therapeutic candidates. We are conducting clinical trials in patients with autoimmune diseases. Explore our pipeline. Our team. We are an integrated team of physicians and scientists working to develop the safest, most effective mRNA cell therapies for our patients. Meet our team.
- Pipeline - Cartesian
Dosing in the first-in-human Phase 1 dose escalation trial...
- Selecta Biosciences Announces Merger with Cartesian Therapeutics
WATERTOWN, Mass. and GAITHERSBURG, MD, November 13, 2023...
- Cartesian Therapeutics Announces Positive Topline Results from Phase 2b ...
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) --...
- Pipeline - Cartesian
Cartesian Therapeutics is a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases. Leveraging its proprietary RNA Armory® platform, Cartesian’s internally manufactured portfolio is purposefully designed to be administered conveniently in an outpatient setting without preconditioning ...
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an ...
Dosing in the first-in-human Phase 1 dose escalation trial is underway to assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma. Cartesian expects to subsequently assess Descartes-15 in autoimmune indications.
Get the latest Cartesian Therapeutics Inc (RNAC) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
13 lis 2023 · WATERTOWN, Mass. and GAITHERSBURG, MD, November 13, 2023 (GLOBE NEWSWIRE) – Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases.
2 lip 2024 · GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced positive topline results from its Phase 2b trial of Descartes-08 in patients with generalized ...
